CAMBRYN BIOLOGICS ANNOUNCES EXPANSION OF ITS MANUFACTURING FACILITY

SARASOTA, Florida – December 14, 2016, Mark P. Famiglio, CEO of Cambryn Biologics, a privately held Delaware corporation, announces that the Company has begun in January 2017, the construction and expansion of its current plasma manufacturing facility.

Cambryn is expanding its currently plasma manufacturing facility by 30%.  The new facility will increase the annual capacity to a approximately 75,000-liter year subject the protein matrix.  Additionally, Cambryn is updating the facility environmental monitoring system; which include temperature, humidity and differential pressure between the classified rooms to be automated and FDA compliant under 21 CFR Part II.   The facility will return to operational status at the end of Q1, 2017 and will be used for the scale up, conformance lots for human clinical trials and commercial production. 

“The improvements will provide Cambryn with a state-of-the-art facility and able to satisfy our development and initial commercial demand into the next decade” said Mark Famiglio

About Cambryn

Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies, advanced wound healing and biosurgical hemostats. The Company specializes in the extraction and purification of human plasma proteins. Cambryn operates a 50,000 square foot state-of-the-art cGMP facility, which incorporates cleanrooms and laboratories.

For additional information contact:
Cambryn Biologics LLC
Mark P. Famiglio
Chief Executive Officer
600 Tallevast Rd – Suite 201
Sarasota, Florida USA 34243
Office: 941-355-7400
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.cambrynbiologics.com

Cambryn Biologics LLC

Cambryn Biologics LLC is a Delaware corporation having its principal facility and offices in Sarasota, Florida. Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies.

logo small

State-of-the-Art Manufacturing Facility

Our facility consists of 50,000 square feet, located adjacent to the Sarasota/Bradenton International Airport, Sarasota, Florida, USA. Cambryn Biologics operates a state-of-the-art manufacturing facility.

Contact Details

Address: 600 Tallevast Rd.
Suite 201 Sarasota, FL 34243

Phone: (941) 355-7400

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.